Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825453 | 1.00 | KISS1R (0.47) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL14947748 | 1.00 | KISS1R (0.47) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL13776588 | 0.94 | KISS1R (0.53) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL16602285 | 0.94 | KISS1R (0.53) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL15132881 | 0.94 | KISS1R (0.53) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL24390551 | 0.89 | DPP7 (0.60) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL18752843 | 0.89 | DPP7 (0.60) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL10126254 | 0.85 | — | — | |
| SCHEMBL12513982 | 0.85 | — | — | |
| SCHEMBL22381010 | 0.84 | GSR (0.48) | DPP7NOS2NOS1NOS3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| WO-2023163536-A1 | NOVEL ANTIBODY DRUG CONJUGATE | 앱티스 주식회사 | 2023-08-31 | — | — | WO | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4190361-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-11659833-B2 | Composition for cryopreservation of bovine reproductive cells and cryopreservation method thereof | BIOVERDE INC. (JP) | 2023-05-30 | — | — | US | disclosed |
| WO-2023012263-A1 | SOLID ORAL PEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022218331-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-10-20 | — | — | WO | disclosed |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
| WO-2022022354-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| WO-2021104120-A1 | POLYETHYLENE GLYCOL CONJUGATE MEDICAMENT, PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110046539-A1 | INTERNAL MEDICAL DEVICES FOR DELIVERY OF THERAPEUTIC AGENT IN CONJUNCTION WITH A SOURCE OF ELECTRICAL POWER | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2206721-A1 | NEUROMEDIN U DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090117656-A1 | STIMULI-RESPONSIVE DEGRADABLE GEL | MITSURU AKASHI (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20080292675-A1 | Antimicrobial medicotechnical product, process for its production and use | AESCULAP AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080262412-A1 | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080242584-A1 | Fabric care composition | PROCTER & GAMBLE COMPANY, THE | 2008-10-02 | — | — | US | disclosed |
| US-20070178136-A1 | Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments | BOSTON SCIENTIFIC SCIMED, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | KISS1R 2360/4885DPP7 2479/4885GNAI3 3836/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | KISS1R 3875/4885DPP7 889/4885GNAI3 1981/4885 |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | KISS1R 1813/4885DPP7 204/4885GNAI3 3712/4885 |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | KISS1R 2117/4885DPP7 1481/4885GNAI3 2268/4885 |
| US-11659833-B2 | Composition for cryopreservation of bovine reproductive cells and cryopreservation method thereof | BOD1L1, RCC1, ALPG | KISS1R 868/4885DPP7 4760/4885GNAI3 2746/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | KISS1R 35/4885DPP7 225/4885GNAI3 224/4885 |
| US-20080292675-A1 | Antimicrobial medicotechnical product, process for its production and use | ANPEP, HM13, PAM | KISS1R 3322/4885DPP7 393/4885GNAI3 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.